Company Description

Ciclomed's CicloMed’s drug development pipeline, Fosciclopirox, holds promise as a novel new agent targeting non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Bladder cancer is a disease with serious unmet need, as patients often endure a lifetime of monitoring, surgical procedures, immunotherapy and chemotherapy treatments.